指南与共识乳腺癌

激素受体阳性乳腺癌女性的辅助内分泌治疗:ASCO临床实践指南重点更新

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update.
指南 / 共识 · J Clin Oncol · 2018-11-19

ASCO对2012至2018年随机临床试验进行系统评价,基于六项试验证据更新辅助内分泌治疗指南。六项研究显示延长芳香化酶抑制剂(AI)治疗未带来总生存优势,但显著降低乳腺癌复发和对侧乳腺癌风险,骨相关毒性更常见。专家组推荐淋巴结阳性患者接受含AI的延长治疗至总共10年,许多淋巴结阴性患者应考虑延长治疗至总共10年。

要点

  • 淋巴结阳性乳腺癌女性推荐接受含AI的延长辅助内分泌治疗,总共至10年。
  • 许多淋巴结阴性女性应考虑延长治疗至总共10年,基于既定预后因素评估复发风险。
  • 延长AI治疗的绝对风险降低幅度有限,低危淋巴结阴性或有限淋巴结阳性者可个体化决定疗程。

核心结论

  • 延长AI治疗与总生存优势无关,但显著降低乳腺癌复发和对侧乳腺癌风险,骨相关毒性更常见。
  • 专家组推荐淋巴结阳性乳腺癌女性接受含AI的延长治疗至总共10年辅助内分泌治疗。
  • 许多淋巴结阴性乳腺癌女性应考虑延长治疗至总共10年,基于既定预后因素评估复发风险。
  • 延长AI治疗的绝对风险降低幅度有限,低危淋巴结阴性或有限淋巴结阳性者可个体化决定疗程。
  • 延长辅助AI治疗的相当一部分获益来自预防第二原发乳腺癌。

研究设计与样本

  • ASCO对2012至2018年的随机临床试验进行系统评价。
  • 指南推荐基于专家组对六项试验证据的审查。
  • 六项纳入研究评估超过5年的AI治疗延长。

主要发现

  • 延长AI治疗与总生存优势无关。
  • 延长AI治疗与安慰剂相比显著降低乳腺癌复发风险和对侧乳腺癌风险。
  • 延长AI治疗组骨相关毒性更常见。
  • 延长辅助AI治疗的相当一部分获益来自预防第二原发乳腺癌。

关键数值与推荐

  • 专家组推荐淋巴结阳性乳腺癌女性接受延长治疗,包括AI,总共至10年辅助内分泌治疗。
  • 许多淋巴结阴性乳腺癌女性应考虑延长治疗至总共10年,基于既定预后因素评估复发风险。
  • 对于低危淋巴结阴性或有限淋巴结阳性癌症,基于风险降低和耐受性考虑个体化确定治疗时长是适当的。
  • 临床医生与患者应就延长辅助内分泌治疗进行共享决策,包括讨论降低乳腺癌复发的绝对获益、预防第二原发乳腺癌及治疗不良反应的影响。

临床怎么用

  • 淋巴结阳性乳腺癌女性推荐接受含AI的延长辅助内分泌治疗至总共10年。
  • 许多淋巴结阴性乳腺癌女性应考虑延长辅助内分泌治疗至总共10年,基于既定预后因素评估复发风险。
  • 低危淋巴结阴性或有限淋巴结阳性癌症可基于风险降低和耐受性考虑个体化治疗时长。
  • 临床医生与患者应就延长辅助内分泌治疗进行共享决策,讨论绝对获益、第二原发乳腺癌预防及不良反应影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To update the ASCO clinical practice guideline on adjuvant endocrine therapy based on emerging data about the optimal duration of aromatase inhibitor (AI) treatment. METHODS: ASCO conducted a systematic review of randomized clinical trials from 2012 to 2018. Guideline recommendations were based on the Panel's review of the evidence from six trials. RESULTS: The six included studies of AI treatment beyond 5 years of therapy demonstrated that extension of AI treatment was not associated with an overall survival advantage but was significantly associated with lower risks of breast cancer recurrence and contralateral breast cancer compared with placebo. Bone-related toxic effects were more common with extended AI treatment. RECOMMENDATIONS: The Panel recommends that women with node-positive breast cancer receive extended therapy, including an AI, for up to a total of 10 years of adjuvant endocrine treatment. Many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors. The Panel noted that the benefits in absolute risk of reduction were modest and that, for lower-risk node-negative or limited node-positive cancers, an individualized approach to treatment duration that is based on considerations of risk reduction and tolerability was appropriate. A substantial portion of the benefit for extended adjuvant AI therapy was derived from prevention of second breast cancers. Shared decision making between clinicians and patients is appropriate for decisions about extended adjuvant endocrine treatment, including discussions about the absolute benefits in the reduction of breast cancer recurrence, the prevention of second breast cancers, and the impact of adverse effects of treatment. Additional information can be found at www.asco.org/breast-cancer-guidelines .

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2018. PMID: 30452337. doi:10.1200/JCO.18.01160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。